2 Dirt Cheap Biotechs to Buy If You're a Contrarian | Nasdaq
Why bluebird bio Is Soaring 11.9% Today
Bluebird bio cuts 30% of its workforce as gene therapy dreams dashed in Europe, delayed in US | Fierce Pharma
BLUE stock on watch as Morgan Stanley predicts regulatory win (NASDAQ:BLUE) | Seeking Alpha
Xconomy: Biotech Roundup: Biogen Rumors, Theranos, Electro-Drugs & More
Why Bluebird Bio Stock Stumbled Today | The Motley Fool
Code of Business Conduct and Ethics
Pfizer Is in Talks to Buy Sickle-Cell Drugmaker, WSJ Reports - Bloomberg
Bluebird bio Inc Stock - BLUE Share Price Today, News and Discussion
JPM 2022: Bluebird bio hopes for clear skies ahead as it gears up for trio of gene therapy launches | Fierce Pharma
Monday's Top Analyst Upgrades and Downgrades: Applied Materials, BJ's Wholesale, Bluebird Bio, eBay, Foot Locker, Kohl's, Salesforce, Snowflake and More – 24/7 Wall St.
Why Bluebird Bio Stock Is Taking Flight Today | The Motley Fool
bluebird bio Stock (NASDAQ:BLUE), Quotes and News Summary - Benzinga
Biotech Stock Mailbag: Bluebird's Sickle Cell Data, Ariad's Faux Suitors, XBiotech Blech - TheStreet
Acceleron To Be Next M&A Target With Rumored $11bn Deal :: Scrip
Stock Down 98% From Peak, Bluebird Bio Could Run Out Of Cash
Could This Beaten-Down Biotech Stock Be the Next Buyout Target? | The Motley Fool
Bluebird bio CMO quits amid a roller coaster year and upcoming split | Fierce Biotech
bluebird bio: A Speculative Buy With Extraordinary Upside Potential (BLUE) | Seeking Alpha
Mergers & Acquisitions - bluebird bio
bluebird bio Reviews: What Is It Like to Work At bluebird bio? | Glassdoor
Gene Editing Stocks To Consider After Bluebird Bio's Breakthroughs
Bluebird bio cuts 30% of its workforce as gene therapy dreams dashed in Europe, delayed in US | Fierce Pharma
bluebird bio completes spin-off of cell therapy company 2seventy bio | Seeking Alpha
ASH18: New data can't lift Bluebird Bio's depressed shares | Fierce Biotech
Will Vertex's Sickle Cell Gambit Sink bluebird bio's Stock? | The Motley Fool
